Assessment of Gut Microbial β-Glucuronidase and β-Glucosidase Activity in Women with Polycystic Ovary Syndrome

Abstract

Objective To identify Gut microbial β-Glucuronidase and β-Glucosidase activity in polycystic ovary syndrome (PCOS) and reveal a possible correlation between gut bacterial enzyme activities and estrogen.

Design Case-Control Study.

Subjects Reproductive-aged women with PCOS (n=23) and controls (n =25) from the Health Centre of Gujarat University.

Interventions Spectrophotometric analysis of β-Glucuronidase and β-Glucosidase activity of fecal samples from patients and clinical parameters (including body mass index, endocrine hormone levels, and hirsutism) collected for correlation analysis.

Primary outcome Identification of gut bacterial β-Glucuronidase and β-Glucosidase activity differences and clinical parameters.

Results Compared to the controls, PCOS women had considerably higher levels of β-glucuronidase activity, having statistically significant p-value (0.05 ± 0.1vs. 0.04± 0.1; p= 0.006). We observed a higher trend of β-glucosidase activity in PCOS women compared to the control (0.13 ± 0.08 vs. 0.09 ± 0.05; p= 0.06).

Conclusion We observed a strong trend toward increased levels of β-glucuronidase and β-glucosidase activity in PCOS women compared to healthy control women. This inference requires further validation through studies with a larger sample size. However, if validated, we suggest that β-glucosidase levels can be considered a putative biomarker for PCOS women with metabolic disturbances and might help personalize the treatment.

• Download figure
• Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Ethics Committee (IEC) of the University School of Sciences, Gujarat University Ref. Letter No. :GU-IEC(NIV)/02/Ph.D./007

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes